Author: Diana

TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc . (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor ...

TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate ...

TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled ...

Aug. 15, 2022 -- Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies. Field Trip Discovery renamed Reunion Neuroscience Inc. (“ Reunion ” or the “ Company ”), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange ...